Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE(®)) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Phil...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Drug Saf
Main Authors: Stein, Anthony, Franklin, Janet L., Chia, Victoria M., Arrindell, Deborah, Kormany, William, Wright, Jacqueline, Parson, Mandy, Amouzadeh, Hamid R., Choudhry, Jessica, Joseph, Guiandre
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2018
Assuntos:
Review Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6475509/
https://ncbi.nlm.nih.gov/pubmed/30565020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40264-018-0760-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares